Skip Nav Destination
Research Watch| March 17 2023
Magrolimab plus Azacitidine Is Safe and Efficacious in High-Risk MDS
Online Issn: 2159-8290
Print Issn: 2159-8274
©2023 American Association for Cancer Research
American Association for Cancer Research
Cancer Discov OF1.
Magrolimab plus Azacitidine Is Safe and Efficacious in High-Risk MDS. Cancer Discov 2023; https://doi.org/10.1158/2159-8290.CD-RW2023-040
Download citation file:
Don't already have an account? Register
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your InstitutionSign in via your Institution